NCT00301964View on ClinicalTrials.gov

Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Recurrent Endometrial Carcinoma
Interventions
BIOLOGICAL

bevacizumab

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

19103

Gynecologic Oncology Group, Philadelphia

All Listed Sponsors
collaborator

Gynecologic Oncology Group

NETWORK

lead

National Cancer Institute (NCI)

NIH

NCT00301964 - Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer | Biotech Hunter | Biotech Hunter